![Wolfram Grüning](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Wolfram Grüning first degree
Entity | Entity type | Industry | |
---|---|---|---|
Nextech Invest AG
![]() Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals.
5
| Private Company | Investment Managers | 5 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Wolfram Grüning via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Arvinas Operations, Inc.
![]() Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member | |
TURG POIN | Pharmaceuticals: Major | Director/Board Member | |
Dartmouth College | College/University | Undergraduate Degree | |
Harvard University
![]() Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Masters Business Admin | |
Karolinska Institutet | College/University | Doctorate Degree | |
Castanea Partners Inc
![]() Castanea Partners Inc Investment ManagersFinance Castanea Partners Inc (Castanea Partners) is a private equity firm founded in 2001 by Robert A. Smith and Brian J. Knez. The firm is headquartered in Newton, Massachusetts. | Investment Managers | Private Equity Investor | |
Silver Lake Capital Partners, Inc.
![]() Silver Lake Capital Partners, Inc. Financial ConglomeratesFinance Silver Lake Capital Partners, Inc. provides investment services. The company is located in Boca Raton, FL | Financial Conglomerates | Corporate Officer/Principal | |
University of Anglia Ruskin | College/University | Undergraduate Degree | |
SYROS PHARMACEUTICALS, INC. | Biotechnology | Founder | |
ARVINAS, INC. | Biotechnology | Director/Board Member | |
Vividion Therapeutics, Inc.
![]() Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
RELAY THERAPEUTICS, INC. | Biotechnology | Founder | |
Arrakis Therapeutics, Inc.
![]() Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member | |
Hexagon Bio, Inc.
![]() Hexagon Bio, Inc. BiotechnologyHealth Technology Hexagon Bio, Inc. operates as a data-driven biotechnology company. It engages in mining of fungal genome data for drugs. The company was founded by Maureen E. Hillenmeyer, Brian T. Naughton, Colin James Bell Harvey and Yi Tang and is headquartered in Menlo Park, CA. | Biotechnology | Director/Board Member | |
A2 Biotherapeutics, Inc.
![]() A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | Miscellaneous Commercial Services | Director/Board Member | |
AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
KRONOS BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
BOUNDLESS BIO, INC. | Biotechnology | Director/Board Member | |
KINNATE BIOPHARMA INC. | Pharmaceuticals: Major | Director/Board Member | |
IconOVir Bio, Inc.
![]() IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Biotechnology | Director/Board Member | |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal |
Statistics
International
United States | 21 |
United Kingdom | 3 |
Germany | 2 |
Sweden | 2 |
Sectoral
Health Technology | 14 |
Finance | 6 |
Consumer Services | 5 |
Commercial Services | 3 |
Operational
Director/Board Member | 13 |
Private Equity Investor | 5 |
Corporate Officer/Principal | 4 |
Founder | 3 |
Independent Dir/Board Member | 3 |
Most connected contacts
- Stock Market
- Insiders
- Wolfram Grüning
- Company connections